Theriva Biologics, Inc. (TOVX) shareholders
Close on Nov 17, 2026Market cap $6.42MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Ryan M. Lane Joint filing with Empery Asset Management, LP (9.99%), Martin D. Hoe (9.99%) | 953,185 | 9.99% | 13G (passive) | Jun 30, 2025 |
| Jeffrey Matthew Gryga Irrevocable Trust Joint filing with Gryga Jeffrey Matthew (7.70%) | 739,211 | 7.70% | 13G (passive) | Oct 24, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TOVX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 486,179 | 1.06% | $121.55K | +293,775 | 0.00% |
| Jane Street Group, LLC | 331,922 | 0.72% | $83.05K | +154,888 | 0.00% |
| Geode Capital Management, LLC | 294,021 | 0.64% | $73.56K | −156,242 | 0.00% |
| Vanguard Fiduciary Trust Co | 241,780 | 0.53% | $60.45K | – | 0.00% |
| Ikarian Capital, LLC | 112,076 | 0.24% | $28.04K | – | 0.00% |
| Virtu Financial LLC | 87,138 | 0.19% | $22.00K | −166,080 | 0.00% |
| Northern Trust Corp | 82,700 | 0.18% | $20.69K | New | 0.00% |
| Renaissance Technologies LLC | 63,710 | 0.14% | $15.94K | New | 0.00% |
| UBS Group AG | 61,053 | 0.13% | $15.26K | −164,571 | 0.00% |
| XTX Topco Ltd | 53,868 | 0.12% | $13.48K | −40,752 | 0.00% |
| Ground Swell Capital, LLC | 35,292 | 0.08% | $8.83K | New | 0.01% |
| Boothbay Fund Management, LLC | 27,646 | 0.06% | $6.92K | – | 0.00% |
| Susquehanna International Group, Llp | 24,064 | 0.05% | $6.02K | New | 0.00% |
| Morgan Stanley | 20,299 | 0.04% | $5.08K | −3,303 | 0.00% |
| Two Sigma Securities, LLC | 19,748 | 0.04% | $4.94K | −85,493 | 0.00% |
| Two Sigma Investments, LP | 15,456 | 0.03% | $3.87K | +15 | 0.00% |
| Schwarz Dygos Wheeler Investment Advisors LLC | 15,000 | 0.03% | $3.75K | – | 0.00% |
| BlackRock, Inc. | 7,504 | 0.02% | $1.88K | – | 0.00% |
| Osaic Holdings, Inc. | 441 | 0.00% | $110 | +433 | 0.00% |
| SBI Securities Co., Ltd. | 358 | 0.00% | $90 | +227 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 26 | 2M | 4.3% | 6 / 5 | 6 / 2 | 1M | 1M |
| Q1 2026 | 22 | 2M | 4.3% | 5 / 5 | 5 / 3 | 1M | 0M |
| Q4 2025 | 21 | 1M | 2.8% | 7 / 7 | 4 / 6 | 1M | 0M |
| Q3 2025 | 20 | 0M | 1.0% | 8 / 5 | 2 / 4 | 0M | 0M |
| Q2 2025 | 17 | 0M | 0.6% | 7 / 2 | 3 / 0 | 0M | 0M |
| Q1 2025 | 10 | 0M | 0.4% | 3 / 1 | 2 / 3 | 0M | 0M |
| Q4 2024 | 10 | 0M | 0.1% | 2 / 2 | 1 / 9 | 0M | 0M |
| Q3 2024 | 18 | 0M | 1.1% | 18 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
4 funds held TOVX in Q2 2026, 61% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TOVX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 486,179 | 1.06% | $121.64K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 284,723 | 0.62% | $80.80K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 26,070 | 0.06% | $7.40K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 31 | 0.00% | $8 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Steven A. Shallcross | CEO and CFO, Director | 250,000 | 0.54% | Jan 6, 2026 |
| Jeffrey J. Kraws | Director | 228,773 | 0.50% | Jan 6, 2026 |
| Jeffrey Alan Wolf | Director | 10,842 | 0.02% | Jan 6, 2026 |
| John J. Monahan | Director | – | – | Jan 6, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Steven A. Shallcross CEO and CFO, Director | Jun 7, 2023 | Buy | +14,000 | $0.69 | $9.66K | 250,000 |
| Steven A. Shallcross CEO and CFO, Director | Jun 6, 2023 | Buy | +26,000 | $0.63 | $16.38K | 236,000 |
| Steven A. Shallcross CEO and CFO, Director | Feb 10, 2023 | Buy | +25,000 | $1.04 | $26.00K | 210,000 |
| Steven A. Shallcross CEO and CFO, Director | Feb 2, 2023 | Buy | +25,000 | $0.94 | $23.50K | 185,000 |
| Steven A. Shallcross CEO and CFO, Director | Jan 25, 2023 | Buy | +25,000 | $0.87 | $21.75K | 160,000 |
| Steven A. Shallcross CEO and CFO, Director | Jan 20, 2023 | Buy | +25,000 | $0.75 | $18.75K | 135,000 |
| Steven A. Shallcross CEO and CFO, Director | Dec 29, 2022 | Buy | +100,000 | $0.44 | $44.00K | 110,000 |
| Steven A. Shallcross CEO and CFO, Director | May 10, 2021 | Buy | +50,000 | $0.49 | $24.50K | 100,000 |
| Steven A. Shallcross CEO and CFO, Director | Aug 23, 2019 | Buy | +50,000 | $0.42 | $21.00K | 50,000 |
| Corp Intrexon 10% owner | Apr 3, 2019 | Sale | −69,161 | $0.65 | $44.95K | 165,332 |
| Corp Intrexon 10% owner | Apr 3, 2019 | Sale | −26,080 | $0.65 | $16.95K | 62,342 |
| Corp Intrexon 10% owner | Apr 2, 2019 | Sale | −9,909 | $0.66 | $6.54K | 234,493 |
| Corp Intrexon 10% owner | Apr 2, 2019 | Sale | −3,737 | $0.66 | $2.47K | 88,422 |
| Corp Intrexon 10% owner | Apr 1, 2019 | Sale | −30,265 | $0.67 | $20.28K | 244,402 |
| Corp Intrexon 10% owner | Apr 1, 2019 | Sale | −11,413 | $0.67 | $7.65K | 92,159 |
| Jeffrey J. Kraws Director | Mar 14, 2017 | Option exercise | +228,773 | $0.09 | $20.59K | 228,773 |
| Scott Tarriff Director | Nov 18, 2016 | Award | +300,000 | – | – | 300,000 |
| Randal J. Kirk 10% owner | Sep 2, 2015 | Buy | +937,500 | $3.20 | $3.00M | 9,613,268 |
| Jeffrey Alan Wolf Director | Apr 1, 2015 | Option exercise | +10,842 | $0.09 | $976 | 10,842 |
| Charles Evan Ballantyne Chief Financial Officer | May 22, 2014 | Buy | +10,000 | $1.35 | $13.50K | 10,000 |
| Steve H. Kanzer 10% owner | Apr 30, 2014 | Sale | −5,003,025 | $1.43 | $7.15M | 2,195,489 |
| Steve H. Kanzer 10% owner | Apr 29, 2014 | Sale | −87,935 | $2.98 | $262.05K | 6,823,268 |
| Steve H. Kanzer 10% owner | Apr 28, 2014 | Sale | −175,177 | $2.86 | $501.01K | 6,911,203 |
| Corp Intrexon 10% owner | Dec 17, 2013 | Buy | +500,000 | $1.00 | $500.00K | 3,625,000 |
| Corp Intrexon 10% owner | Dec 17, 2013 | Buy | +2,000,000 | $1.00 | $2.00M | 8,675,768 |
| Jeffrey Scott Riley CEO and President, Director | Jan 7, 2013 | Buy | +5 | $1.71 | $9 | 7,505 |
| Jeffrey Scott Riley CEO and President, Director | Jan 7, 2013 | Buy | +2,895 | $0.17 | $492 | 10,400 |
| Jeffrey Scott Riley CEO and President, Director | Jan 3, 2013 | Buy | +2,000 | $1.71 | $3.42K | 7,500 |
| Jeffrey Scott Riley CEO and President, Director | Jan 3, 2013 | Buy | +2,800 | $1.75 | $4.90K | 5,500 |
| Jeffrey Scott Riley CEO and President, Director | Jan 2, 2013 | Buy | +2,700 | $1.78 | $4.81K | 2,700 |
| Randal J. Kirk 10% owner | Oct 29, 2012 | Buy | +3,125,000 | $1.60 | $5.00M | 3,125,000 |
| James S. Kuo Chairman, CEO & President, Director | Aug 30, 2011 | Buy | +4,500 | $0.69 | $3.10K | 4,500 |
| Lyman Max Lyon Jr CEO & President, Director | Dec 9, 2009 | Returned to company | −25,000 | $0.45 | $11.25K | 0 |
| Lyman Max Lyon Jr CEO & President, Director | Dec 8, 2009 | Returned to company | −20,000 | $0.48 | $9.60K | 25,000 |
| Lyman Max Lyon Jr CEO & President, Director | Dec 7, 2009 | Award | +45,000 | $0.38 | $17.10K | 45,000 |
| Steve H. Kanzer Chief Executive Officer, Director | Apr 11, 2008 | Buy | +500 | $0.90 | $450 | 348,146 |
| Steve H. Kanzer Chief Executive Officer, Director | Apr 11, 2008 | Buy | +2,400 | $0.89 | $2.14K | 347,646 |
| Steve H. Kanzer Chief Executive Officer, Director | Apr 11, 2008 | Buy | +6,200 | $0.86 | $5.33K | 345,246 |
| Steve H. Kanzer Chief Executive Officer, Director | Apr 11, 2008 | Buy | +1,000 | $0.85 | $850 | 339,046 |
| Steve H. Kanzer Chief Executive Officer, Director | Apr 11, 2008 | Buy | +2,300 | $0.83 | $1.91K | 338,046 |
| Steve H. Kanzer Chief Executive Officer, Director | Apr 11, 2008 | Buy | +500 | $0.81 | $405 | 335,746 |
| Steve H. Kanzer Chief Executive Officer, Director | Apr 11, 2008 | Buy | +9,500 | $0.80 | $7.60K | 335,246 |
| Steve H. Kanzer Chief Executive Officer, Director | Apr 11, 2008 | Buy | +500 | $0.79 | $395 | 325,746 |
| Steve H. Kanzer Chief Executive Officer, Director | Apr 11, 2008 | Buy | +3,100 | $0.98 | $3.04K | 375,246 |
| Steve H. Kanzer Chief Executive Officer, Director | Apr 11, 2008 | Buy | +1,000 | $0.96 | $960 | 372,146 |
| Steve H. Kanzer Chief Executive Officer, Director | Apr 11, 2008 | Buy | +1,866 | $0.95 | $1.77K | 371,146 |
| Steve H. Kanzer Chief Executive Officer, Director | Apr 11, 2008 | Buy | +2,650 | $0.94 | $2.49K | 369,280 |
| Steve H. Kanzer Chief Executive Officer, Director | Apr 11, 2008 | Buy | +8,484 | $0.93 | $7.89K | 366,630 |
| Steve H. Kanzer Chief Executive Officer, Director | Apr 11, 2008 | Buy | +9,900 | $0.92 | $9.11K | 358,146 |
| Steve H. Kanzer Chief Executive Officer, Director | Apr 11, 2008 | Buy | +100 | $0.91 | $91 | 348,246 |
| A. Joseph Rudick Director | Jan 29, 2008 | Option exercise | +27,106 | $0.09 | $2.44K | 57,267 |
| Daniel J. Dorman Director | Nov 9, 2007 | Buy | +247,542 | $2.22 | $549.54K | 742,626 |
| Daniel J. Dorman Director | Nov 9, 2007 | Buy | +6,189 | $2.22 | $13.74K | 18,566 |
| Capital Investments Ltd. Ridgeback 10% owner | Nov 9, 2007 | Option exercise | +618,855 | $0.74 | $457.95K | 1,856,565 |
| Steve H. Kanzer CEO, Director, 10% owner | Jul 25, 2007 | Buy | +5,000 | $7.42 | $37.10K | 315,946 |
| Steve H. Kanzer CEO, Director, 10% owner | Jul 25, 2007 | Buy | +200 | $7.16 | $1.43K | 316,146 |
| Steve H. Kanzer CEO, Director, 10% owner | Jul 25, 2007 | Buy | +5,000 | $7.09 | $35.45K | 325,246 |
| Steve H. Kanzer CEO, Director, 10% owner | Jul 25, 2007 | Buy | +2,000 | $7.14 | $14.28K | 320,246 |
| Steve H. Kanzer CEO, Director, 10% owner | Jul 25, 2007 | Buy | +2,100 | $7.15 | $15.02K | 318,246 |
| Steve H. Kanzer CEO, Director, 10% owner | Jul 24, 2007 | Buy | +2,400 | $7.11 | $17.06K | 309,346 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Theriva Biologics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 93,707 shares on Oct 13, 2026 over the last 90 days.
See a number that looks wrong?